Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 전재범 | - |
dc.date.accessioned | 2018-09-03T10:08:47Z | - |
dc.date.available | 2018-09-03T10:08:47Z | - |
dc.date.issued | 2013-10 | - |
dc.identifier.citation | ARTHRITIS AND RHEUMATISM, v. 65, NO Special SI, Page. 1203-1203 | en_US |
dc.identifier.issn | 0004-3591 | - |
dc.identifier.uri | https://onlinelibrary.wiley.com/doi/abs/10.1002/art.38216 | - |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/74729 | - |
dc.description.abstract | Anti-tumor necrosis factor alpha (Anti-TNF ) therapy is often used in patients with rheumatic diseases who do not respond to conventional treatment. Risk of tuberculosis infection is high in patients receiving anti-TNF treatments. Therefore, tuberculosis infection prophylaxes are recommended prior to anti-TNF therapy if a tuberculin skin test or interferon-gamma release assay (IGRA) is positive. However, little data is available on the conversion of IGRAs in patients with rheumatic diseases who received anti-TNF treatment. We evaluated the utility of follow-up IGRAs for the diagnosis of latent tuberculosis infection and newly developing tuberculosis in patients receiving TNF antagonists. | en_US |
dc.language.iso | en | en_US |
dc.publisher | WILEY-BLACKWELL | en_US |
dc.subject | Rheumatology | en_US |
dc.title | Follow-Up Testing Of Interferon-Gamma Release Assays For The Diagnosis Of Hidden Tuberculosis Infection In Patients Receiving Tumor Necrosis Factor Alpha Antagonists | en_US |
dc.type | Article | en_US |
dc.relation.no | Special SI | - |
dc.relation.volume | 65 | - |
dc.identifier.doi | 10.1002/art.38216 | - |
dc.relation.page | 1203-1203 | - |
dc.relation.journal | ARTHRITIS AND RHEUMATISM | - |
dc.relation.code | 2013009027 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF MEDICINE[S] | - |
dc.sector.department | DEPARTMENT OF MEDICINE | - |
dc.identifier.pid | junjb | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.